Nanni Huser

2.3k total citations
15 papers, 999 citations indexed

About

Nanni Huser is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Nanni Huser has authored 15 papers receiving a total of 999 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 8 papers in Oncology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Nanni Huser's work include PI3K/AKT/mTOR signaling in cancer (5 papers), Cancer-related Molecular Pathways (4 papers) and Advanced Breast Cancer Therapies (2 papers). Nanni Huser is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (5 papers), Cancer-related Molecular Pathways (4 papers) and Advanced Breast Cancer Therapies (2 papers). Nanni Huser collaborates with scholars based in United States and Australia. Nanni Huser's co-authors include Adam Siddiqui-Jain, William G. Rice, Denis Drygin, Sean O’Brien, Chris Proffitt, Kenna Anderes, David M. Ryckman, Nicole Streiner, Mayuko Omori and Caroline B. Ho and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Nanni Huser

15 papers receiving 983 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nanni Huser United States 8 737 238 100 84 82 15 999
Christian Borgo Italy 18 702 1.0× 224 0.9× 86 0.9× 70 0.8× 105 1.3× 38 991
Paolo Bonvini Italy 16 721 1.0× 229 1.0× 105 1.1× 101 1.2× 43 0.5× 34 1.0k
Roberta Pireddu United States 10 465 0.6× 240 1.0× 100 1.0× 44 0.5× 59 0.7× 14 718
Nicole Streiner United States 9 1.1k 1.6× 312 1.3× 63 0.6× 105 1.3× 75 0.9× 16 1.4k
Lynn Ueno United States 9 630 0.9× 221 0.9× 126 1.3× 148 1.8× 54 0.7× 13 910
Kevin Hudson United Kingdom 17 779 1.1× 223 0.9× 145 1.4× 156 1.9× 53 0.6× 30 1.1k
Theonie Anastassiadis United States 5 602 0.8× 181 0.8× 51 0.5× 58 0.7× 76 0.9× 6 817
Chris Proffitt United States 7 1.4k 1.9× 362 1.5× 71 0.7× 140 1.7× 81 1.0× 12 1.7k
Vishal Pendharkar Singapore 12 714 1.0× 270 1.1× 57 0.6× 67 0.8× 59 0.7× 15 1.0k
Banibrata Sen United States 15 555 0.8× 358 1.5× 85 0.8× 135 1.6× 45 0.5× 21 923

Countries citing papers authored by Nanni Huser

Since Specialization
Citations

This map shows the geographic impact of Nanni Huser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nanni Huser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nanni Huser more than expected).

Fields of papers citing papers by Nanni Huser

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nanni Huser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nanni Huser. The network helps show where Nanni Huser may publish in the future.

Co-authorship network of co-authors of Nanni Huser

This figure shows the co-authorship network connecting the top 25 collaborators of Nanni Huser. A scholar is included among the top collaborators of Nanni Huser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nanni Huser. Nanni Huser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Anders, Lars, Todd Van Arsdale, Sudhakar Chintharlapalli, et al.. (2024). 354P Synergistic preclinical efficacy through combination of the CDK4 and CDK2 selective inhibitors, PF-07220060 and PF-07104091, respectively, in HR+ HER2- breast cancer. Annals of Oncology. 35. S365–S365. 1 indexed citations
2.
Shen, Chen, Ming Qiu, Nanni Huser, et al.. (2024). Abstract 5709: PF-07104091, a first-in-class CDK2-selective inhibitor for the treatment of HR+/HER2- breast cancer and CCNE1high ovarian cancer. Cancer Research. 84(6_Supplement). 5709–5709. 6 indexed citations
3.
Kashyap, Manoj Kumar, Deepak Kumar, Brett H. Simmons, et al.. (2017). Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia. Journal of Hematology & Oncology. 10(1). 112–112. 49 indexed citations
4.
5.
Shan, Qin, Fang Wang, Andreas Giannakou, et al.. (2017). Purine Nucleotide Availability Regulates mTORC1 Activity through the Rheb GTPase. Cell Reports. 19(13). 2665–2680. 95 indexed citations
6.
Siddiqui-Jain, Adam, Joshua Bliesath, Mayuko Omori, et al.. (2012). CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination Therapy. Molecular Cancer Therapeutics. 11(4). 994–1005. 86 indexed citations
7.
Bliesath, Joshua, Nanni Huser, Mayuko Omori, et al.. (2012). Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells. Cancer Letters. 322(1). 113–118. 59 indexed citations
8.
Haddach, Mustapha, Michael K. Schwaebe, Jerome Michaux, et al.. (2012). Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics. ACS Medicinal Chemistry Letters. 3(7). 602–606. 114 indexed citations
9.
Hein, Nadine, Megan J. Bywater, Kim Stanley, et al.. (2011). Inhibition of RNA Polymerase I Transcription by CX-5461 As a Therapeutic Strategy for the Cancer-Specific Activation of p53 in MLL-Rearranged Acute Myeloid Leukemias. Blood. 118(21). 1548–1548. 4 indexed citations
10.
11.
Siddiqui-Jain, Adam, Denis Drygin, Nicole Streiner, et al.. (2010). CX-4945, an Orally Bioavailable Selective Inhibitor of Protein Kinase CK2, Inhibits Prosurvival and Angiogenic Signaling and Exhibits Antitumor Efficacy. Cancer Research. 70(24). 10288–10298. 421 indexed citations
12.
Anderes, Kenna, Nicole Streiner, May Omori, et al.. (2010). Effect of CX-4945, a selective bioavailable small molecule inhibitor of protein kinase CK2, on gemcitabine antitumor activity in A2780 ovarian cancer.. Journal of Clinical Oncology. 28(15_suppl). e13522–e13522. 3 indexed citations
13.
Lundgren, Karen, Hong Zhang, Nanni Huser, et al.. (2009). BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Molecular Cancer Therapeutics. 8(4). 921–929. 140 indexed citations
14.
Drygin, Denis, Josh Bliesath, Caroline B. Ho, et al.. (2009). Abstract C198: CX-4945, a novel small molecule inhibitor of CK2 protein kinase, reduces hyperactivated Akt signaling and synergizes with Akt inhibitors in breast cancer cells. Molecular Cancer Therapeutics. 8(12_Supplement). C198–C198. 1 indexed citations
15.
Jessen, Katayoun A., Karen Froning, Andres Gutierrez, et al.. (2007). In vitro and in vivo antitumor activities of SGX523, a novel MET inhibitor. Molecular Cancer Therapeutics. 6. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christian Borgo Breakdown of academic impact, for papers by Paolo Bonvini Breakdown of academic impact, for papers by Roberta Pireddu Breakdown of academic impact, for papers by Nicole Streiner Breakdown of academic impact, for papers by Lynn Ueno Breakdown of academic impact, for papers by Kevin Hudson Breakdown of academic impact, for papers by Theonie Anastassiadis Breakdown of academic impact, for papers by Chris Proffitt Breakdown of academic impact, for papers by Vishal Pendharkar Breakdown of academic impact, for papers by Banibrata Sen
Rankless by CCL
2026